PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
168.96%
Revenue growth exceeding 1.5x VET's 9.30%. David Dodd would verify if faster growth reflects superior business model.
18.29%
Cost growth above 1.5x VET's 8.59%. Michael Burry would check for structural cost disadvantages.
2212.00%
Gross profit growth exceeding 1.5x VET's 10.81%. David Dodd would verify competitive advantages.
759.62%
Margin expansion exceeding 1.5x VET's 1.38%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-3.93%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
116.67%
Other expenses growth while VET reduces costs. John Neff would investigate differences.
-0.66%
Operating expenses reduction while VET shows 2.11% growth. Joel Greenblatt would examine advantage.
7.45%
Total costs growth 1.1-1.25x VET's 5.98%. Bill Ackman would demand justification.
-7.48%
Interest expense reduction while VET shows 3.69% growth. Joel Greenblatt would examine advantage.
-20.00%
D&A reduction while VET shows 8.93% growth. Joel Greenblatt would examine efficiency.
144.32%
Similar EBITDA growth to VET's 139.84%. Walter Schloss would investigate industry trends.
-104.06%
EBITDA margin decline while VET shows 6.48% growth. Joel Greenblatt would examine position.
129.91%
Operating income growth exceeding 1.5x VET's 19.21%. David Dodd would verify competitive advantages.
111.12%
Operating margin growth exceeding 1.5x VET's 26.09%. David Dodd would verify competitive advantages.
260.90%
Other expenses growth while VET reduces costs. John Neff would investigate differences.
135.49%
Pre-tax income growth exceeding 1.5x VET's 80.78%. David Dodd would verify competitive advantages.
113.19%
Pre-tax margin growth 1.25-1.5x VET's 82.41%. Bruce Berkowitz would examine sustainability.
113.28%
Tax expense growth 1.25-1.5x VET's 90.59%. Martin Whitman would scrutinize strategy.
152.75%
Net income growth exceeding 1.5x VET's 74.01%. David Dodd would verify competitive advantages.
119.61%
Net margin growth exceeding 1.5x VET's 76.22%. David Dodd would verify competitive advantages.
152.11%
EPS growth exceeding 1.5x VET's 75.00%. David Dodd would verify competitive advantages.
152.26%
Diluted EPS growth exceeding 1.5x VET's 75.00%. David Dodd would verify competitive advantages.
1.40%
Share count reduction below 50% of VET's 1.26%. Michael Burry would check for concerns.
0.99%
Diluted share reduction below 50% of VET's 1.26%. Michael Burry would check for concerns.